In this work, a problem of selecting a subset of molecules, which are potential lead candidates for drug discovery, is considered. Such molecule subset selection problem is formulated as a portfolio optimization, well known and studied in financial management. The financial return, more precisely the return rate, is interpreted as return rate from a potential lead and calculated as a product of gain and probability of success (probability that a selected molecule becomes a lead), which is related to performance of the molecule, in particular, its (bio-)activity. The risk is associated with not finding active molecules and is related to the level of diversity of the molecules selected in portfolio. It is due to potential of some molecules to contribute to the diversity of the set of molecules selected in portfolio and hence decreasing risk of portfolio as a whole. Even though such molecules considered in isolation look inefficient, they are located in sparsely sampled regions of chemical space and are different from more promising molecules. One way of computing diversity of a set is associated with a covariance matrix, and here it is represented by the Solow-Polasky measure. Several formulations of molecule portfolio optimization are considered taking into account the limited budget provided for buying molecules and the fixed size of the portfolio. The proposed approach is tested in experimental settings for three molecules datasets using exact and/or evolutionary approaches. The results obtained for these datasets look promising and encouraging for application of the proposed portfoliobased approach for molecule subset selection in real settings.
The most-widely used formulation of portfolio selection problem was de-96 veloped by Markowitz early in the 50s [15] . It addresses a way of selecting 97 a combination of several assets called portfolio that collectively would be of 98 the best quality and be as diverse as possible. Hence, portfolio optimiza-99 tion should simultaneously satisfy two conflicting goals, minimizing risk and 100 maximizing expected return of the portfolio, that is formally:
(1)
x i = 1;
x i ∈ [0, 1], i = 1, . . . , N T otal ,
where N T otal is the number of assets; x i is the proportion of money invested E(x) → max;
(2) σ 2 (x) → min;
where c i refers to the cost of an asset, which can be different for different 173 assets.
174
The set of feasible portfolios F is now the subset of portfolios in S with
Earlier VS for drug discovery was formulated as a multiobjective opti-177 mization problem in [17] , where both activity and diversity were maximized 178 simultaneously. Our portfolio-based formulation is similar, however, different 179 diversity measure based on Solow-Polasky diversity [23] is used, see section making) one could also establish beforehand a criterion by which the best 188 solution on the Pareto front is selected (a priori decision making).
189
The investment management suggests a large number of measures to eval-190 uate return-to-risk ratios of portfolios, relatively to time period (e. g., stan-191 dard deviation), to market behavior (e. g., beta ratio), to benchmark asset 192 (e. g., tracking error, excess return, Sharpe ratio). The Sharpe ratio, also 193 called reward-to-volatility ratio, is the most widely used risk-adjusted per-194 formance index [5] and will be used here.
195
The Sharpe ratio can be defined with the help of the capital allocation line 196 (CAL). It is a straight line on the return-risk graph (see Figure 1 ) that shows 197 all possible combinations of risky portfolios with the risk-free asset r f ≥ 0.
198
The risk-free asset, r f , has a return that is smaller than the minimal expected 199 return of an efficient portfolio r f < r min , and it assumes risk-free investment.
200
The optimal CAL corresponds to the portfolios with lowest risk for any given 201 value of return r > r f . The slope of the optimal CAL is a sub-derivative of 202 the function that defines the Pareto front of efficient portfolios. The point 203 at which the CAL touches the front of efficient portfolios corresponds to the 204 Sharpe ratio that provides an optimal risky portfolio.
205
Here, the risk free investment is chosen to be r f = −B, as this will be the exact return if we do not invest in the research. Then the Sharpe ratio is defined as comparing two portfolios, the one with the higher Sharpe ratio gives more 208 return per risk. Finding the portfolio with maximal Sharpe ratio yields the 209 following nonlinear integer programming problem:
where B refers to the budget, which in research projects if not spent is lost. The problem with the Markowitz (2) and optimal Sharpe ratio (3) for-213 mulations is that they both favor selection of empty portfolios as they may 214 be best at minimizing risk of any losses. One way to neutralize this effect 215 is to require a fixed number of assets to be selected into the portfolio. This 216 problem formulation is referred to as fixed size portfolio selection and it as-217 sumes that the number of assets to be selected is limited to a specific number 218 N P ortf olio . Then, in addition to the formulation (2) or (3), a constraint of the 219 following form is assumed:
where e is in {0, 1} N T otal ; each coordinate is either 0 or 1, summing up to 221 portfolio of N P ortf olio size (with N P ortf olio << N T otal not all molecules being 222 selected in portfolio out of N T otal ).
223
This formulation is equivalent to the 0-1 quadratic knapsack problem. 
13
The gain is the same for each successful molecule G i = G and is zero 236 for unsuccessful molecules. problem that is formulated as follows:
x · e = N P ortf olio ;
and is referred in the text as the Markowitz model with fixed size portfolios.
255
Here, x i , i = 1, . . . , N T otal , denote the decision variables; x i = 1 means 256 that the i-th molecule is selected and x i = 0 means that it is not selected; x i = N P ortf olio , where N P ortf olio is the size of the portfolio.
260
We consider two real valued objective functions defined on S, σ 2 (x) = x Qx 261 and E(x) = r x. Each portfolio x is associated with a 2-dimensional evalu-262 ation vector in the objective space, (σ 2 (x), E(x)) T , where the risk objective 263 is to be minimized and the return objective is to be maximized; r and Q are 264 defined as before in (1).
265
The computation of return E(x) and risk σ 2 (x) is discussed next. The return E(x) is defined as the gains minus the losses. For the expected return it is important to realize that money from the budget that is not invested in molecules is lost. Therefore, the losses will be B and the gains will be the cumulated gains from molecules that become successful drugs. Hence,
Due to the probabilistic nature of the return (we get it only in case of successful drug(s)), it can be modeled as a random variable. Letx i denote a random variable of Bernoulli type that models the uncertain return on investment in a molecule i:
Then, the expected return of a molecule i is defined by:
Following the classical model of Markowitz, the risk σ 2 (x) can be ex-266 pressed by means of a covariance matrix Q as follows:
where q ij is a correlation between the return from the i-th molecule r i and here. Since minimizing risk of selecting similar assets into a portfolio can also be 327 interpreted as maximizing diversity of selected portfolio of assets, different 328 formulations of diversity can be taken in the portfolio selection problem.
A posteriori

329
Here, we propose to use Solow-Polasky diversity as a second objective instead 330 of the risk measure calculated as a variance of the returns.
331
The Solow-Polasky diversity measure is calculated as the sum of the en-332 tries of the inverse of the correlation matrix for selected assets:
where F (x) −1 ij is the inverse of the correlation matrix for all selected assets.
334
Then, the two objectives to be optimized are: the return and the diversity 335 of the portfolio, which can be presented in the following model:
Even though both a posteriori approaches use the correlation function sug- is optimized subject to the other objective fixed and expressed as a constraint.
377
To obtain, say N P areto , points on the Pareto front, we solve the following series 378 of N P areto SOCOPs for ascending expected returns E j , j = 1, . . . , N P areto :
x · c ≤ B;
x = N P ortf olio ;
x i ∈ {0, 1}, i = 1, . . . , N T otal .
The resulting optima will be called x * j , and their risk σ 2 * j and return E * Then, we can calculate the distance between two molecules as a dissimi-481 larity measure, which is diversity:
where Sim T is Tanimoto similarity.
483
Second, the information on (bio-)activities of the candidate molecules 484 needs to be translated into success probabilities. Activity a i is normally 485 given as logarithmized activity l i ; in this case, we can use a i = e l i .
486
Moreover, from experience chemists know an average probability of suc-487 cessp, for the sake of the argument estimated asp = 1/100. Let us consider 488 a vector of N T otal activities (exponentiated) A = {a 1 , . . . , a N T otal } and let 489 P = {p 1 , . . . , p N T otal } denote the success probabilities. Then, the average 490 probability of success can be calculated as:
and we know that activities are proportional to success probability. Hence, for some constant k it holds:
By substituting p i in (10) as defined in (11), we can obtain k:
Combining 11 and 12 we get:
Third, the gain from a new lead compound (i.e. a molecule that may activity before selection and from the same sorted dataset top 1000, 2500 and 531 5000 most active molecules were selected. The datasets are sorted based on 532 activity because chemists usually do not consider molecules below the cut-off 533 activity. Thus, larger datasets, e.g. with 2500 and 5000 molecules, contain 534 molecules with lower activity on average, when compared to smaller datasets 535 with higher average activity, e.g. with 1000 molecules.
536
To avoid the situation when the average success probability of a given 537 molecule is lower in a bigger dataset when compared to the average suc-538 cess probability of the same molecule in a smaller dataset, its calculation is 539 adjusted. In particular, the average probability of success of a molecule is 540 computed in such a way that it is independent of the size of the considered 541 dataset, and in such a way it suits better to datasets with a non-uniform 542 distribution of activities.
543
As before it is assumed that success probability is proportional to the ac-544 tivity. However, now the average probabilityp 1000 is fixed to be proportional 545 to the average activityā 1000 of the 1000 molecules dataset:
which leads to the k computed as:
Hence, this fixed average probabilityp 1000 of the 1000 molecules dataset will 549 be used for computing the probabilities of success of molecules p i in the 550 datasets with 2500 and 5000 molecules. 
565
The number of crossover points was set to 1, and the probability of crossover portfolios P (t), t = 1, 2, . . . was set to 10 in order to conform with the setting 573 we used to sample the Pareto front by means of quadratic programming.
574
For fair comparison of MOEAs, in all experiments we run NSGA-II for 575 10, 000 iterations and SMS-EMOA for 100, 000 for the dataset of 1000 molecules.
576
This is due to the fact that SMS-EMOA creates 1 offspring at each iter-577 ation, whereas NSGA-II creates 100 offspring at each iteration. For the 578 larger datasets, we increased the number of iterations with the same factor 579 as the dataset size. That is, for the 2500 molecules dataset we ran NSGA- To make comparison fair we run all algorithms for circa 10 minutes for the obtained at the 13th iteration has the highest Sharpe ratio value and should 675 be selected as the most promising one for potential drug discovery. Next, we 676 will analyze the content of this portfolio.
677
In Figure 5 (b) , the molecules of the 1000 dataset are presented. Here, 678 the molecules are allocated according to their activity (see X-axis) and price 679 (see Y-axis), respectively. The molecules selected in the Sharpe optimal 680 portfolio are marked in red and the non-selected molecules are depicted in 681 black. As can be observed from this figure, not only the cheapest molecules 682 are selected and not only the most active ones, but some balance between 683 price and activity is reached for the portfolio of molecules as a whole. 
